A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability

PLoS Computational Biology

Volumn 8, Issue 2, 2012, Pages

  Iwami, Shingo ^a   Haeno, Hiroshi ^b   Michor, Franziska ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; GENES; IMMUNE SYSTEM; VIRUSES;

CELL POPULATIONS; EVOLUTIONARY PROCESS; FOREIGN AGENTS; GENETIC INSTABILITY; GENOME FUNCTIONS; HIGH MUTATION RATE; HUMAN IMMUNE SYSTEMS; MALIGNANT TRANSFORMATIONS; SYSTEM FUNCTIONS; TUMOUR CELLS;

TUMORS;

TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ARTICLE; CARCINOGENESIS; CELL POPULATION; EPIGENETICS; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; MOLECULAR EVOLUTION; TUMOR CELL; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNOLOGY; ANIMAL; BIOLOGY; CELL TRANSFORMATION; DISEASE COURSE; GENETIC EPIGENESIS; GENETICS; HUMAN GENOME; IMMUNOLOGY; MUTATION; NEOPLASM; PHENOTYPE; STATISTICAL MODEL; THEORETICAL MODEL;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; COMPUTATIONAL BIOLOGY; DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENOME, HUMAN; HUMANS; IMMUNE SYSTEM; MODELS, STATISTICAL; MODELS, THEORETICAL; MUTATION; NEOPLASMS; PHENOTYPE;

EID: 84861173716     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002370     Document Type: Article

References (52)

1. Ehrlich P, (1909) Ueber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 5: 73-290.
2. Burnet FM, (1957) Cancer, a biological approach. Br Med J 1: 841-847.
3. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, et al. (2001) Regulation of cutaneous malignancy by gamma-delta T cells. Science 294: 605-609.
4. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, et al. (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
5. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD, (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998.
6. Dunn GP, Old LJ, Schreiber RD, (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360.
7. Dunn GP, Bruce AT, Sheenan KC, Shankaran V, Uppaluri R, et al. (2005) A critical function for type I interferons in cancer immunoediting. Nat Immunol 6: 722-729.
8. Herberman RB, Holden HT, (1978) Natural cell-mediated immunity. Adv Cancer Res 27: 305-377.
9. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani A, et al. (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191: 661-668.
10. Cerwenka A, Lanier LL, (2001) Natural killer cells, viruses and cancer. Nat Rev Immunol 1: 41-49.
11. Smyth MJ, Crowe NY, Godfrey DI, (2001) NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 13: 459-463.
12. Street SE, Hayakawa Y, Zahn Y, Lew AM, MacGregor D, et al. (2004) Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med 199: 879-884.
13. Engel AM, Svane IM, Mouritsen S, Rygaard J, Clausen J, et al. (1996) Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression. APMIS 104: 629-639.
14. Smyth MJ, Dunn GP, Schreiber RD, (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90: 1-50.
15. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, et al. (2004) Regulation of the innate and adaptive immune response by Stat-3 signaling in tumor cells. Nat Med 10: 48-54.
16. Haura EB, Turkson J, Jove R, (2005) Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2: 315-324.
17. Khong HT, Restifo NP, (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3: 999-1005.
18. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, et al. (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cellsL their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182: 18-32.
19. Garcia-Lora A, Algarra I, Garrido F, (2003) MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 195: 346-355.
20. Schreiber H, Wu TH, Nachman J, Kast WM, (2002) Immunodominance and tumor escape. Semin Cancer Biol 12: 25-31.
21. Salazar-Onfray F, Charo J, Petersson M, Freland S, Noffz G, et al. (1997) Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J Immunol 159: 3195-3202.
22. Igney FH, Krammer PH, (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2: 277-288.
23. Pettit SJ, Seymour K, O'Flaherty E, Kirby JA, (2002) Immune selection in neoplasia: towards a microevolutionary model of cancer development. Br J Cancer 82: 1900-1906.
24. Lengauer C, Kinzler KW, Vogelstein B, (1997) Genetic instability in colorectal cancer. Nature 386: 623-627.
25. Lengauer C, Kinzler KW, Vogelstein B, (1998) Genetic instabilities in human cancers. Nature 396: 643-649.
26. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, et al. (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392: 300-303.
27. Loeb LA, (2001) A mutator phenotype in cancer. Cancer Res 61: 3230-3239.
28. Grady WM, Carethers JM, (2008) Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135: 1079-1099.
29. Eigen M, (2002) Error catastrophe and antiviral strategy. Proc Natl Acad Sci U S A 99: 13374-13376.
30. Summers J, Litwin S, (2006) Examining the theory of error catastrophe. J Virol 80: 20-26.
31. Anderson JP, Daifuku R, Loeb LA, (2004) Viral error catastrophe by mutagenic nucleosides. Annu Rev Microbiol 58: 183-205.
32. Crotty S, Cameron CE, Andino R, (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 98: 6895-6900.
33. Pariente N, Airaksinen A, Domingo E, (2003) Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouse disease virus. J Virol 77: 7131-7138.
34. Kuznetsov V, Makalkin IA, Taylor MA, Perelson AS, (1994) Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull Math Biol 56: 295-321.
35. Komarova NL, Wodarz D, (2003) Evolutionary dynamics of mutator phenotypes in cancer: implications for chemotherapy. Cancer Res 63: 6635-6642.
36. Vladar HP, Gonzalez JA, (2003) Dynamic response of cancer under the influence of immunological activity and therapy. J Theor Biol 227: 335-348.
37. Sole RV, Deisboeck TS, (2004) An error catastrophe in cancer? J Theor Biol 228: 47-54.
38. D'Onofrio A, (2005) A general framework for modeling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences. Physica D 208: 220-235.
39. De Pillis LG, Radunskaya AE, Wiseman CL, (2005) A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res 65: 7950-7958.
40. Brumer Y, Michor F, Shankhnovich EI, (2006) Genetic instability and the quasispecies model. J Theor Biol 241: 216-222.
41. De Boer RJ, Hogeweg P, Dullens HF, De Weger RA, Den Otter W, (1985) Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical model. J Immunol 134: 2748-2758.
42. Davis DM, (2006) Intrigue at the immune synapse. Sci Am 294: 48-55.
43. Dustin ML, Colman DR, (2002) Neural and immunological synaptic relations. Science 298: 785-789.
44. Janeway C, Travers P, Walport M, Shlomchik MJ, (2004) Immunobiology: the immune system in health and disease New York Garland Science.
45. De Boer RJ, (2007) Understanding the failure of CD8+ T-cell vaccination against simian/human immunodeficiency virus. J Virol 81: 2838-2848.
46. Ogg GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, et al. (1999) Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 73: 797-800.
47. Bull JJ, Meyers LA, Lachmann M, (2005) Quasispecies made simple. PLoS Comput Biol 1: 450-460.
48. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME, (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 4: 299-308.
49. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 11: 783-792.
50. Nowak AK, Robinson BW, Lake RA, (2003) Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63: 4490-4496.
51. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
52. Lake RA, Robinson BW, (2005) Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 5: 5397-5405.